Dr Specht on the Significance of Data for Mogamulizumab vs SOC in Denmark for Patients With MF/SS

“At the moment, we are hoping that mogamulizumab is approved in Denmark [for all patients with MF or SS].… We are hoping that [these data from] the study aid in this process.”

Lena Specht, MD, DMSc, a professor of oncology at the Faculty of Health Sciences and Chief Oncologist at Rigshopitalet at the University of Copenhagen, discussed data with mogamulizumab-kpkc (Poteligeo) in patients with mycosis fungoides (MF) or Sézary syndrome (SS) in comparison with standard-of-care (SOC) regimens in Denmark, which were presented at the 6th World Congress of Cutaneous Lymphomas (WCCL). In addition to diving into what data were shown from the study, Specht discussed the potential significance of these data in clinical practice both in Denmark and globally.

Specht began by pointing out how mogamulizumab has only been approved in Denmark for the treatment of patients with MF or SS who have already received 1 prior line of systemic therapy. An application for the approval of mogamulizumab for use in all patients with MF or SS in Denmark is currently under review, supported by data from the phase 3 MAVORIC trial (NCT01728805) as well as these real-world data, she followed up. Specht noted that the study also adds to the general body of knowledge of mogamulizumab’s effect on patients with MF and SS.

Specht then explained how mogamulizumab improved outcomes vs SOC regimens in patients in Denmark, and that similar studies, which enrolled patients in both the United Kingdom and Australia, that were also presented at WCCL 2026 shared similar data with the treatment. In addition to improved outcomes, another reason why the field is hoping for an expanded approval of mogamulizumab in MF and SS is due to the tolerable adverse effect (AE) profile associated with the treatment, she added. Ultimately, Specht concluded by emphasizing that a tolerable safety profile is important, since regimens other than mogamulizumab are often associated with burdensome AEs.